STAb-T, a new form of immunotherapy to treat solid tumours shows therapeutic potential in animal models with non-small cell lung cancer. The new strategy is designed to strengthen the defensive cells.
Only 20-40% of patients respond positively to immunotherapy, and these rates vary across different types of cancer. Researchers now identified five key factors that determine response and survival.
Currently, it is difficult to predict whether a cancer patient will respond to immunotherapy or not. A new method to quantify the heterogeneity of the tumour microenvironment aims to improve this.
Immunocompromised patients are at greatest risk of developing severe Covid-19 after an infection. While early antiviral treatments yield best results, even late-onset therapies still show benefits.
Brazilian researchers have identified a key mechanism of Sars-CoV-2 to manipulate its host’s immune defense. This discovery could pave the way for the development of novel therapies.
Systemic lupus erythematodes can lead to severe kidney damage. However, until now, the cause for this remained unclear. New research has now revealed the underlying mechanism.
In rhesus pregnancy, antibodies from the pregnant mother can lead to anaemia for the foetus in the uterus. A new study suggests that a drug could serve as a non-surgical alternative.
Researchers discovered islands of highly potent immune cells in the vicinity of glioblastomas. This may open up prospects for new therapies for these aggressive brain tumours.
New research reveals a promising approach to developing a universal influenza vaccine that confers lifetime immunity against an evolving virus considered most likely to trigger the next pandemic.
Why does the immune system sometimes fail to control the development of bowel cancer? UK and Dutch researchers discovered how cancer cells use a genetic "switch" to evade detection.
Scientists discover how the production of antibodies is regulated in allergy and infections. This opens the door to new therapies, without affecting the beneficial response of the immune system.
Pancreatic cancer stem cells exploit an antibacterial protein to evade the immune system. Removing this protein could pave the way to more effective immunotherapy, new research suggests.
Immunotherapy increases survival rates in kidney cancer, but does not work for everyone. A research team developed a new method to predict which patients will benefit from it.
New research into a life-threatening, but underestimated complication in lung transplants not only provides new insights, but also approaches for early detection and timely treatment.
New research challenges assumptions about the origin of rheumatoid arthritis, which are probably too simple. The findings may point towards improved diagnostics of this painful autoimmune disease.
After a stroke or heart attack, the risk of infection is increased – however, why this happens was unknown. Now, researchers found a previously unknown cause – and a therapeutic approach.
New research provides cause for optimism that long Covid can resolve over time. Following people from the first wave of Covid-19, it monitored the longevity of immune abnormalities after an infection.
Beckman Coulter Diagnostics announced ahead of the ESCMID Global congress (formerly ECCMID) that it has extended the menu of DxI 9000 Immunoassay Analyzer* assays.
Findings from the largest UK study of patients hospitalised with Sars-CoV-2 infection show that long Covid leads to ongoing inflammation which can be detected in the blood.
Researchers discovered three distinct immunological endophenotypes of multiple sclerosis, defined by specific blood immune signatures. This opens new avenues for personalized treatment strategies.
A study found immune cells in breast tissue of healthy women carrying BRCA1 or BRCA2 gene mutations show signs of ‘exhaustion’. This opens new possibilities for cancer prevention.
New study results explore the long-term effects of infection with Sars-CoV-2, and challenge the idea that vaccine immunity fades quickly.
How does a coronavirus infection cause neurological symptoms such as headaches, memory problems, and fatigue? A new study points to a different reason than previously assumed.
Researchers have unveiled a detailed understanding of immune responses in cancer, potentially paving the way for the development of new therapeutic strategies, the team hopes.
Researchers in Japan and the US have developed technology to robustly augment the amount of MHC class I molecules in cancer cells. This makes them easier to find and destroy for the immune system.